Home  »  Science   »  Analysts Say Allogene Therapeutics Inc. (NASDAQ:AL...

Analysts Say Allogene Therapeutics Inc. (NASDAQ:ALLO) Can Really Get To $55.00 In 12 Months

In last trading session, Allogene Therapeutics Inc. (NASDAQ:ALLO) saw 3.16 million shares changing hands with its beta currently measuring 0.51. Company’s recent per share price level of $10.84 trading at -$0.69 or -5.98% at ring of the bell on the day assigns it a market valuation of $1.60B. That closing price of ALLO’s stock is at a discount of -157.01% from its 52-week high price of $27.86 and is indicating a premium of 40.68% from its 52-week low price of $6.43. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.16 million shares which gives us an average trading volume of 1.68 million if we extend that period to 3-months.

For Allogene Therapeutics Inc. (ALLO), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 1.90. Splitting up the data highlights that, out of 19 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 5 suggested the stock as a Hold whereas 14 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.61 in the current quarter.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.


Allogene Therapeutics Inc. (NASDAQ:ALLO) trade information

Upright in the red during last session for losing -5.98%, in the last five days ALLO remained trading in the red while hitting it’s week-highest on Friday, 09/16/22 when the stock touched $10.84 price level, adding 22.74% to its value on the day. Allogene Therapeutics Inc.’s shares saw a change of -27.35% in year-to-date performance and have moved -22.57% in past 5-day. Allogene Therapeutics Inc. (NASDAQ:ALLO) showed a performance of -27.20% in past 30-days. Number of shares sold short was 22.43 million shares which calculate 8.53 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $27.56 to the stock, which implies a rise of 60.67% to its current value. Analysts have been projecting $15.00 as a low price target for the stock while placing it at a high target of $55.00. It follows that stock’s current price would drop -407.38% in reaching the projected high whereas dropping to the targeted low would mean a loss of -38.38% for stock’s current value.

Allogene Therapeutics Inc. (ALLO) estimates and forecasts

Statistics highlight that Allogene Therapeutics Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added 11.87% of value to its shares in past 6 months, showing an annual growth rate of -29.10% while that of industry is 1.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -15.10% in the current quarter and calculating -21.10% decrease in the next quarter. This year revenue growth is estimated to fall -99.70% from the last financial year’s standing.

11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $10k for the same. And 11 analysts are in estimates of company making revenue of $10k in the next quarter that will end on Sep 2022. Company posted $44k and $10k of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -77.30% while estimating it to be 0.00% for the next quarter.

In 2022, company’s earnings growth rate is likely to be around 9.00% while estimates for its earnings growth in next 5 years are of 1.00%.

ALLO Dividends

Allogene Therapeutics Inc. is more likely to be releasing its next quarterly report between February 23 and February 28 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Allogene Therapeutics Inc. (NASDAQ:ALLO)’s Major holders

Insiders are in possession of 29.93% of company’s total shares while institution are holding 65.11 percent of that, with stock having share float percentage of 92.93%. Investors also watch the number of corporate investors in a company very closely, which is 65.11% institutions for Allogene Therapeutics Inc. that are currently holding shares of the company. Tpg Group Holdings (sbs) Advisors, Inc. is the top institutional holder at ALLO for having 18.72 million shares of worth $481.01 million. And as of Sep 29, 2021, it was holding 13.03% of the company’s outstanding shares.

The second largest institutional holder is TPG GP A, LLC, which was holding about 18.72 million shares on Mar 30, 2022. The number of shares represents firm’s hold over 13.03% of outstanding shares, having a total worth of $170.51 million.

On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Horizon Fund-Capital Opportunity Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 4.08 million shares of worth $46.49 million or 2.84% of the total outstanding shares. The later fund manager was in possession of 2.86 million shares on Mar 30, 2022, making its stake of worth around $26.03 million in the company or a holder of 1.99% of company’s stock.

Leave a Comment

Your email address will not be published.

On Key

Related Posts